Target- |
MechanismAnion transport proteins modulators [+1] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.AU |
First Approval Date24 Oct 2017 |
A randomized, double-blind, placebo-controlled investigation of the safety, tolerability and pharmacokinetics of 1% SPL7013 nasal spray in healthy volunteers when administered four times a day for 14 days
A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SN38-SPL9111 (DEP®-SN38), a SN38 dendrimer conjugate, in patients with advanced solid tumours. - SN38-SPL9111 in advanced solid tumours
A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CTX-SPL9111 (a cabazitaxel (CTX)-dendrimer conjugate) in patients with advanced solid tumours
100 Clinical Results associated with Starpharma Pty Ltd.
0 Patents (Medical) associated with Starpharma Pty Ltd.
100 Deals associated with Starpharma Pty Ltd.
100 Translational Medicine associated with Starpharma Pty Ltd.